Symptomatic hypocalcemia in a patient with latent hypoparathyroidism and breast carcinoma with bone metastasis following administration of pamidronate

Internal Medicine

Volumn 37, Issue 4, 1998, Pages 396-397

  Çömlekçi, Abdurrahman ^a   Biberoǧlu, Sevinç ^a   Hekimsoy, Zeliha ^a   Okan, Inci ^a   Pişkin, Özden ^a   Şekeroǧlu, Binnaz ^a   Alakavuklar, Mehmet ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

Bisphosphonate; Malignancy

Indexed keywords

ALKALINE PHOSPHATASE; CALCITRIOL; CALCIUM; GLUCONATE CALCIUM; PAMIDRONIC ACID; PARATHYROID HORMONE; PHOSPHATE;

ADULT; ARTICLE; BONE ATROPHY; BONE METASTASIS; BONE PAIN; BREAST CARCINOMA; CALCIUM BLOOD LEVEL; CASE REPORT; FEMALE; HUMAN; HYPOCALCEMIA; HYPOPARATHYROIDISM; INTRAVENOUS DRUG ADMINISTRATION; MUSCLE SPASM;

EID: 0031799349     PISSN: 09182918     EISSN: None     Source Type: Journal    
DOI: 10.2169/internalmedicine.37.396     Document Type: Article

References (11)

1. Coleman RE, Rubens RD. The clinical course of bone metastases from breast cancer. Br J Cancer 55: 61, 1987.
2. van Holten-Verzantvoort AT, Kroon HM, Bijvoet OL, et al. Palliative pamidronate treatment in patients with bone metastases from breast cancer. J Clin Oncol 11: 491, 1993.
3. Tyrrell CJ. Aredia Multinational Cooperative Group. Role of pamidronate in the management of bone metastases from breast cancer: results of a non-comparative multicenter phase II trial. Ann Oncol 5 Suppl 7: S37, 1994.
4. Fleisch H. Bisphosphonates-preclinical. in: Fleisch H, Ed. Bisphosphonates in Bone Disease, 2 ed. Parthenon Publishing Group. New York, 1995, p. 31.
5. Compston JE. The therapeutic use of biphosphonates. BMJ 309: 711, 1994 (see comments).
6. Boonekamp PM, Lowik CW, van der Wee-Pals LJ, van Wijk-van Lennep ML, Bijvoet OL. Enhancement of the inhibitory action of APD on the transformation of osteoclast precursors into resorbing cells after dimethylation of the amino group. Bone Miner 2: 29, 1987.
7. Boonekamp PM, van der Wee-Pals LJ, van Wijk-van Lennep ML, Thesing CW, Bijvoet OL. Two modes of action of biphosphonates on osteoclastic resorption of mineralized matrix. Bone Miner 1: 27, 1986.
8. Fitton A, McTavish D. Pamidronate. A review of its pharmacological properties and therapeutic efficacy in resorptive bone disease. Drugs 41: 289, 1991.
9. Jodrell DI, Iveson TJ, Smith IE. Symptomatic hypocalcemia after treatment with high-dose aminohydroxypropylidene diphosphonate. Lancet 1: 622, 1987 (letter).
10. Landman JO, Schweitzer DH, Frolich M, Hamdy NA, Papapoulos SE. Recovery of serum calcium concentrations following acute hypocalcemia in patients with osteoporosis on long-term oral therapy with the biphosphonate pamidronate. J Clin Endocrinol Metab 80: 524, 1995.
11. Landman JO, Hamdy NA, Pauwels EK, Papapoulos SE. Skeletal metabolism in patients with osteoporosis after discontinuation of long term treatment with the bisphosphonate pamidronate. J Clin Endocrinol Metab 80: 3465, 1995.